Nuclear Medicine Therapy

Nuclear Medicine Therapy Led by Dr. Ish*ta B. Sen, a seasoned clinician with extensive expertise, FMRI, Gurugram offers PSMA, PRRT, TARE & Terbium-161 therapies.

As India’s 1st Nuclear Oncology Centre, we provide world-class, affordable care. Start your recovery journey today!

In Cancer Treatment, Timing Is Everything.When it comes to advanced therapies like Terbium-161 (Tb-161), even a slight d...
14/05/2025

In Cancer Treatment, Timing Is Everything.

When it comes to advanced therapies like Terbium-161 (Tb-161), even a slight delay in isotope availability can disrupt the entire treatment plan. But at Fortis Memorial Research Institute (FMRI), Gurugram, patients don’t have to wait.

Thanks to our reliable sourcing partnership with TerThera (Netherlands), we ensure a stable, timely, and uninterrupted supply of medical-grade Tb-161—essential for precision radioligand therapy like PSMA and DOTATATE-based treatments.

✅ Why it matters:
Tb-161 therapy is not a single dose—it’s a carefully planned multi-cycle treatment. A missed or delayed dose can impact your results.
✅ What we offer:
• Pre-scheduled Tb-161 deliveries through 2025
• Advance planning and assured therapy timelines
• Clinical guidance from experts like Dr. Ish*ta B. Sen, Senior Director, Nuclear Oncology

📅 Planning your treatment?
Align your therapy with our delivery schedule and avoid delays.

More info: https://nuclearmedicinetherapy.in/post/terbium-161-without-delays-how-our-centre-ensures-a-reliable-supply-for-timely-cancer-treatment

📩 Share your reports or seek a second opinion:
👉 info@nuclearmedicinetherapy.in

Don’t let logistics interrupt your healing. With us, timing is on your side.

13/05/2025

Terbium vs. Lutetium The Radioactive Half-Life Showdown!

Dr. Ish*ta B Sen gives presents an Introduction to Terbium and its comparison to Lutetium in terms of decay protocol and half-life.

"Terbium is a very cool molecule because it has a very similar kind of a decay protocol as compared to lutetium. It's very similar to lutetium. It has a similar kind of a half-life. So the half-life of lutetium is about 6.6 days. The half-life of this is abou"Terbium is a very cool molecule because it has a very similar kind of a decay protocol as compared to lutetium. It's very similar to lutetium. It has a similar kind of a half-life. So the half-life of lutetium is about 6.6 days. The half-life of this is about 6.8 days."

Watch the full Video: https://nuclearmedicinetherapy.in/post/terbium-161-cancer-therapy-faqs

Know more: https://nuclearmedicinetherapy.in/

Book a Second Opinion: https://nuclearmedicinetherapy.in/consult-us

Disclaimer: This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. Please consult with a qualified healthcare professional for any medical concerns or treatment decisions.

12/05/2025

Terbium The Cancer-Killing Advantage it has over other Radio Ligands

Dr. Ish*ta B Sen explains the unique advantage of Terbium in cancer treatment due to its emission of Auger and conversion electrons, which effectively target residual cancer cells.

Dr. Ish*ta B Sen - "The advantage of terbium is that along with a beta decay it also emits certain particles called Auger electrons or conversion electrons. Now these Auger electrons or conversion electrons are small very energetic electrons which what they have a very low pe*******on in tissue so they are very energetic but they manage to kill cells only in the local vicinity now what happens is that often when you have a tumor there are single cancer cells which are residual on the surface of the cells and these cells often escape the more penetrating beta rays which come out of lutetium and then these cells are responsible for increased recurrences."

Watch the full Video: https://nuclearmedicinetherapy.in/post/terbium-161-cancer-therapy-faqs

Know more: https://nuclearmedicinetherapy.in/

Book a Second Opinion: https://nuclearmedicinetherapy.in/consult-us

Disclaimer: This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. Please consult with a qualified healthcare professional for any medical concerns or treatment decisions.

11/05/2025

Auger Electrons Target Single Cancer Cells Low Recurrence of Cancer

Dr. Ish*ta B Sen explains how Auger electrons target single cancer cells and the hypothesis that using terbium could lower recurrence rates compared to lutetium.
Now what these Auger electrons do is that they manage to target these single cancer cells which are sitting on the surface of the tumor. So the hypothesis is that the recurrence rates when we use terbium would be lower than when you use lutetium.

Watch the full Video: https://nuclearmedicinetherapy.in/post/terbium-161-cancer-therapy-faqs

Know more: https://nuclearmedicinetherapy.in/

Book a Second Opinion: https://nuclearmedicinetherapy.in/consult-us

Disclaimer: This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. Please consult with a qualified healthcare professional for any medical concerns or treatment decisions.

10/05/2025

Terbium 161_Less Radioisotope, More Radiation for Tumor Treatment!

Dr. Ish*ta B Sen, summarizes the advantages of Terbium over Lutetium in cancer treatment, highlighting its potential for reduced radioisotope dosage and enhanced radiation delivery to tumors.

Dr. Ish*ta B Sen - "With terbium, with almost 40 percent less of radioisotope as compared to lutetium, you can deliver the same amount of radiation to the tumor. Taking it a step forward, with the same amount of terbium as lutetium, you can deliver 40 percent more radiation to the tumor. So it can work both ways."

Watch the full Video: https://nuclearmedicinetherapy.in/post/terbium-161-cancer-therapy-faqs

Know more: https://nuclearmedicinetherapy.in/

Book a Second Opinion: https://nuclearmedicinetherapy.in/consult-us

Disclaimer: This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. Please consult with a qualified healthcare professional for any medical concerns or treatment decisions.

09/05/2025

Dr. Ish*ta B Sen - "We know that the response of tumors is more when you are able to deliver a higher and more concentrated form of radiation and we have seen this when we have used alpha emitters. right so with alpha emitters because they are more energetic particles they deliver almost you know seventy five hundred times more radiation as compared to the beta emitters we know that the cell kill is higher so terbium is somewhere in the middle so it gives us more radiation as compared to lutetium without having the toxicity which is associated with the alpha emitters so Probably, terbium can be a kind of a bridge between the beta and the alpha"

Watch the full Video: https://nuclearmedicinetherapy.in/post/terbium-161-cancer-therapy-faqs

Know more: https://nuclearmedicinetherapy.in/

Book a Second Opinion: https://nuclearmedicinetherapy.in/consult-us

Disclaimer: This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. Please consult with a qualified healthcare professional for any medical concerns or treatment decisions.

08/05/2025

Dr. Ish*ta B Sen - "With terbium the other advantage is that you are able to deliver almost 40 percent more radiation per unit of radioisotope which is injected into the patient So which basically means that as compared to lutetium you can give almost 30 to 40 percent less of radioisotope and deliver the same amount of radiation to the tumor."

Watch the full Video: https://nuclearmedicinetherapy.in/post/terbium-161-cancer-therapy-faqs

Know more: https://nuclearmedicinetherapy.in/

Book a Second Opinion: https://nuclearmedicinetherapy.in/consult-us

Disclaimer: This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. Please consult with a qualified healthcare professional for any medical concerns or treatment decisions.

07/05/2025

Is Terbium-161 therapy given in cycles? Yes—and here's why it matters.
is administered in multiple cycles to maximize impact against both visible tumors and hidden micrometastases in advanced prostate cancer.

💡 Each cycle =
✔️ Sustained tumor pressure
✔️ Chance to monitor response
✔️ Opportunity to adjust treatment safely using precision dosimetry

Discover how cyclic dosing improves outcomes and personalizes care in radioligand therapy.

🎥 Watch now and learn more.
📖 Full blog: https://nuclearmedicinetherapy.in/post/is-terbium-161-given-in-cycles

Disclaimer: This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. Please consult with a qualified healthcare professional for any medical concerns or treatment decisions.

07/05/2025

Where does Terbium-161 come from?

Terbium-161 ( ) is at the forefront of precision cancer treatment, especially for advanced prostate cancer. But do you know where and how it's produced?

In this video, we take you behind the scenes of its reliable supply chain—from advanced nuclear reactors to your treatment center—ensuring safe, timely, and effective care for patients.

✅ Watch now to understand the science behind the source.
🌍 Learn why stable supply matters in life-saving radioligand therapy.

📖 Full post: https://nuclearmedicinetherapy.in/post/where-is-terbium-161-sourced-from

Disclaimer: This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. Please consult with a qualified healthcare professional for any medical concerns or treatment decisions.


01/05/2025

So, people ask me: "Patients who don't respond to Lutetium—will they respond to Terbium?" I don't know.
We don't have any data that actually looks at patients who have not responded to Lutetium and whether they have an enhanced response to Terbium.
The theoretical benefit is there, so there is a possibility that patients who did not respond to Lutetium, or who had an inadequate response to Lutetium, or had a response and are now progressing, may have an advantage by receiving Terbium instead of Lutetium.
But we still don't have the data.
The data that we do have, which comes more from preclinical studies, suggests that recurrence rates with Terbium will probably be much lower than with Lutetium. This is due to Terbium's ability to kill single cells—those residual cells that are actually responsible for recurrence.
It may be that Terbium is used versus Lutetium as a first-line therapy, rather than using Terbium in patients who fail Lutetium. That could be the protocol in the future.
There is a large study currently happening in Australia called the VIOLET study, led by Professor Michael Hofman and his team. They are conducting a head-to-head comparison between Terbium and Lutetium.
Their initial results are very encouraging, and they show that Terbium definitely has much better efficacy compared to Lutetium.
So, who knows—maybe in the future, Terbium will replace Lutetium as a first-line therapy.
Know more: https://nuclearmedicinetherapy.in/
Book a Second Opinion: https://nuclearmedicinetherapy.in/consult-us
Watch the full Video: https://nuclearmedicinetherapy.in/post/terbium-161-cancer-therapy-faqs

Disclaimer: This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. Please consult with a qualified healthcare professional for any medical concerns or treatment decisions.

30/04/2025

Tb-161 offers several important advantages:

It delivers 40% more radiation dose to tumor cells per molecule compared to Lu-177.
It emits Auger and conversion electrons in addition to beta particles, leading to highly localized cell kill.
Because more radiation is concentrated in the tumor per molecule, lower total radioactivity can be administered, reducing potential toxicity to organs like the kidneys and bone marrow.
Know more: https://nuclearmedicinetherapy.in/

Book a Second Opinion: https://nuclearmedicinetherapy.in/consult-us

Watch the full Video: https://nuclearmedicinetherapy.in/post/terbium-161-cancer-therapy-faqs

Disclaimer: This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. Please consult with a qualified healthcare professional for any medical concerns or treatment decisions.

Transarterial Radioembolization (TARE) with Yttrium-90 (Y-90) is a crucial treatment for liver transplant candidates wit...
04/03/2025

Transarterial Radioembolization (TARE) with Yttrium-90 (Y-90) is a crucial treatment for liver transplant candidates with hepatocellular carcinoma (HCC). It effectively downstages tumors, prevents progression during wait times, and improves post-transplant survival. TARE outperforms TACE, offering better tolerance, fewer side effects, and enhanced cost-effectiveness.

Know more: https://nuclearmedicinetherapy.in/post/transarterial-radioembolization-tare-as-a-treatment-for-liver-transplant-candidates



Disclaimer: This information is intended for general knowledge and informational purposes only, and does not constitute medical advice. Please consult with a qualified healthcare professional for any medical concerns or treatment decisions.

Address

Fortis Hospital, Sector 44
Gurugram
122002

Telephone

+919811127080

Website

Alerts

Be the first to know and let us send you an email when Nuclear Medicine Therapy posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Nuclear Medicine Therapy:

Shortcuts

Share

Category

The Nuclear Oncology Experts

The team of Nuclear Oncology Experts is a group of dedicated Nuclear Medicine Physicians, Dosimetrists, Radiochemists and Nuclear Medicine technologists with extensive experience in Nuclear Medicine Diagnostics and Therapies. Operating from the Department of Nuclear Medicine & Molecular Imaging, Fortis Memorial Research Institute (FMRI), Gurgaon in the state of Haryana, India, the centre is the first-of-its-kind dedicated Nuclear Oncology Diagnostic and Therapeutic setup in India.

With internationally trained experts and world class facilities, the team ensures that the regimens and protocols followed at the centre are at par with the highest standards in the world. All cases are first discussed in a multi-disciplinary board that includes Medical, Radiation & Surgical Oncologists; Pathologists and Radiologists. Each member of this team is specially trained in performing highly sophisticated Targeted Radionuclide Therapy that targets the tumours with minimal damage to the surrounding tissue.

The Nuclear Oncology Experts team is led by Dr. Ish*ta Sen, Director & Head, Department of Nuclear Medicine at FMRI. Trained at the MSKCC for thyroid cancer, she is one of the pioneers of Radionuclide Therapy especially Targeted Alpha Therapy in India.

The other dynamic and qualified doctors in the team are Dr. Vineet Pant, MBBS, DNB, FEBNM Fellow Theranostics and Dr. Sugandha Dureja, MBBS, DNB, FEBNM Fellow Theranostics.